Investigation of liposome formulation effects on rivastigmine transport through human colonic adenocarcinoma cell line (CACO-2)

Pharmazie

Volumn 65, Issue 1, 2010, Pages 32-40

  Degim Z ^a   Mutlu, N B ^a   Yilmaz, S ^b   Essiz D ^c   Nacar, A ^d  

^a GAZI UNIVERSITY   (Turkey)

^b Food and Mouth Diseases Institute   (Turkey)

^c KAFKAS UNIVERSITY   (Turkey)

^d MUSTAFA KEMAL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLODEXTRIN DERIVATIVE; DIMETHYL BETA CYCLODEXTRIN; LIPOSOME; RIVASTIGMINE; TAUROCHOLIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL STRAIN CACO 2; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG TRANSPORT; ENCAPSULATION; ENZYME STABILITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; ZETA POTENTIAL;

ABSORPTION; ANIMALS; BETA-CYCLODEXTRINS; BIOLOGICAL TRANSPORT, ACTIVE; BRAIN; CACO-2 CELLS; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CHOLINESTERASE INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMPOUNDING; EXCIPIENTS; HUMANS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; PARTICLE SIZE; PHENYLCARBAMATES; TAUROCHOLIC ACID;

EID: 76149095641     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2010.9179     Document Type: Article

References (39)

1. Agid Y, Dubois B, Anand R, Gharabawi G (1998) Efficacy and tolerability of rivastigmine in patients with dementia of the alzheimer type. Curr Therap Res 59: 833-845.
2. Alcala MM, Vivas NM, Hospital S, Camps P, Torreno Diego M, Badia A (2003) Charcterization of the anticholinesterase activitiy of two tacrinhuperizin A hybrids. Neuropharmacol 44: 749-755.
3. AllenTM(1997) Liposomes: Opportunities in drug delivery. Drugs 4: 8-14.
4. Artursson P, Karlsson J (1991) Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Com 175: 880-885.
5. Audus KL, Bartel RL, Hidalgo IJ, Borchardt RT (1990) The use of cultured epithelial and endothelial cells for drug transport and metabolism studies. Pharm Res 7: 435-449.
6. Boulenc X, Marti E, Joyeux H, Roques C, Berger Y, Fabre G (1993) Importance of the paracellular pathway for the transport of a new bisphosphonate using the human Caco-2 monolayers model. Biochem pharmacol 46: 1591-1600.
7. Bozdaǧ S, Vural İ, Çapan Y, Dalkara T (2002) Beyin tümörlerinin tedavisinde ilaç taşiyici sistemlerin uygulanmasi. FABAD J Pharm Sci 27: 89-104.
8. st ed., New York, pp. 54-66.
9. Doraiswamy MP, Krishman RRK, Anand R, Sohn H, Danylunk J, Hartman RD (2002) Long-term effects of rivastigmine in moderately severe Alzheimer's disease. Does early initiation of theraphy offer sustained? Prog Neuro-Psychopharmacol Biol Psychiat 26: 705-712.
10. th ed., Thomson PDR, Montvale, pp. 2252-2260.
11. Ellman GL, Courtney D, Andre V, Featherstone RM (1961) A new and rapid colorimetric determination acetylcholinesterase activity. Biochem Pharmacol 7: 88-95.
12. Eskander MF, Nagykery NG, Leung EY, Khelghati B, Geula C (2005) Rivastigmine is a potent inhibitor of aceyl- and butyrylcholinesterase in Alzheimer's plaques and tangles. Brain Res 1060: 144-152.
13. Farlow MR (2001) Pharmacokinetic profiles of current therapies for alzheimer's disease: implications for switching to galantamine. Clin Therap 23-Suppl.A: A13-A24.
14. th ed., Canada, pp. 89-104.
15. Garcia-Garcia E, Andrieux K, Gil S, Couvreur P (2005) Colloidal carriers and blood-brain barrier (BBB) translocation: A way to deliver drugs to the brain? Int J Pharm 298: 274-292.
16. Garberg P, Eriksson P, Schipper N, Sjöström B (1999) Automated absorption assessment using Caco-2 cells cultured on both sides of polycarbonate membranes. Pharm Res 16: 441-445.
17. Garberg P, Ball M, Borg N, Cecchelli R, Fenart L, Hurst RD, Lindmark T, Mabondzo A, Nilsson JE, Raub TJ, Stanimirovic D, Terasaki T, Öberg JO, Österberg T (2005) In vitro models for the blood-brain barriers. Toxicol in Vitro 19: 299-334.
18. Higuchi T (1960) Physical chemical analysis of percutaneous absorption from creams and ointments. J Soc Cos Chem 11: 85-97.
19. Jann MW, Shirley KL, Small GW (2002) Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 41: 719-739.
20. Lasic DD (1998) Novel applications of liposomes. Tibtech 16: 307-321.
21. Leonard BE (2004) Pharmacotherapy in the treatment of Alzheimer's disease: an update. World Psychiatry 3: 84-88.
22. Lundquist S, Renftel M, Brillault J, Fenart L, Cecchelli R, Dehouck MP (2002) Prediction of drug transport through the blood-brain barrier in vivo: A comparison between two in vitro cell models. Pharm Res 19: 976-981.
23. Mayeux R, Sano M (1999) Treatment of Alzheimer's Disease. The New Eng J Med 341: 1670-1677.
24. Meaney CM, O'Driscoll CM (2000) A comparison of the permeation enhancement potential of simple bile salt and mixed bile salt:fatty acid micellar systems using the Caco-2 cell culture model. Int J Pharm 207: 21-30.
25. Mura P, Maestrelli F, González-Rodríguez ML, Michelacci I, Ghelardini C, RabascoAM(2007)Development, characterization and in vivo evaluation of benzocaine loaded liposomes. Eur J Pharm Biopharm 67: 86-95.
26. Mustafa C, Borioni A, Giudice MRD, Gatta RF, Meneguzzi A, Volpe MT (2007) Synthesis and cholinesterase activity of phenylcarbamates releated to rivastigmine, a therapeutic agent for Alzheimer's disease. Eur J Med Chem 37: 91-109.
27. Mutlu B, Deǧim Z, Yilmaz Ş , Eşiz D, Kirilmaz L, Günkaya G (2008) Investigation of Rivastigmine Transport Through Human Colon Carsinoma Cells, Caco-2, 35th Annual Meeting of Controlled Release Society, 12-16 July, New York City, New York, USA, p. 690.
28. Othman AA, Syed SA, Newman AH, Eddington ND (2007) Transport, metabolism and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Therap 320: 344-353.
29. Potts RO, Guy RH (1992) Predicting skin permeability. Pharm Res 9: 663-669.
30. Raiman J, Törmaletho S, Yritys K, Junginger HE, Mönkkönen J (2003) Effects of various absorbtion enhancers on transport of clodronate through Caco-2 cells. Int J Pharm 261: 129-136.
31. Scarpini E, Scheltens P, Feldman H (2003) Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2: 539-547.
32. Shabbitts JA, Chiu GNC, Mayer LD (2002) Development of an in vitro drug release assay that accuretly predicts in vivo drug retention for liposomebased delivery systems. J Control Release 84: 161-70.
33. Sharma A, Sharma US (1997) Liposomes in drug delivery: progress and limitations. Int J Pharm 154: 123-140.
34. Snape MF, Misra A, Murray TK, De Souza RJ, Williams JL, Cross AJ, Green AR (1999) A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066. Neuropharmacol 38: 181-193.
35. Stevenson CL, Augustijins PF, Hendren RW (1999) Use of Caco-2 cells and LC/MS/MS to screen a peptide combinatorial library for permeable structures. Int J Pharm 177: 103-115.
36. Uhumwangho MU, Okor RS (2005) Current trends in the production and biomedical applications of liposomes: a review. J Med Biomed Res 4: 9-21.
37. Williams BR, Nazarians A, Gill M (2003) A review of rivastigmine: a reversible cholinesterase inhibitor. Clin Therap 25: 1651-1653.
38. Wang Q, Rager JD, Weinstein K, Kardos PS, Dobson GL, Li J (2005) Evaluation of the MDR- MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm 288: 349-359.
39. Zerrouk N, Corti G, Ancillotti S, Maestrelli F, Cirri M, Mura P (2006) Influence of cyclodextrins and chitosan, separately or in combination on glyburide solubility and permeability. Eur J Pharm Biopharm 62: 241-246.